Invex Therapeutics

About:

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment.

Website: https://invextherapeutics.com/

Description:

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.

Total Funding Amount:

$26M

Headquarters Location:

Subiaco, Western Australia, Australia

Founded Date:

2019-01-01

Contact Email:

info(AT)invextherapeutics.com

Founders:

Alexandra Sinclair, Jason Loveridge

Number of Employees:

1-10

Last Funding Date:

2020-05-22

IPO Status:

Public

Industries:

© 2025 bioDAO.ai